EFMC
BCRX icon

Empire Financial Management Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Empire Financial Management Company’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$780K – 212
2025
Q4 		$780K Buy
+100,000
New +$723K 0.17% 125
2025
Q1 		– Sell
-35,000
Closed -$263K – 200
2024
Q4 		$263K Sell
35,000
-24,000
-41% -$182K 0.08% 176
2024
Q3 		$448K Hold
59,000
– – 0.14% 154
2024
Q2 		$365K Sell
59,000
-20,000
-25% -$110K 0.12% 158
2024
Q1 		$401K Buy
79,000
+5,500
+7% +$30.9K 0.13% 158
2023
Q4 		$440K Buy
73,500
+26,000
+55% +$151K 0.17% 141
2023
Q3 		$336K Buy
47,500
+5,000
+12% +$35.9K 0.15% 148
2023
Q2 		$299K Buy
42,500
+12,500
+42% +$100K 0.12% 165
2023
Q1 		$250K Buy
+30,000
New +$289K 0.1% 178

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Empire Financial Management Company's BCRX Position: Q1 2026 in Review

Empire Financial Management Company sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 100,000 shares — an estimated $780K sold.

Empire Financial Management Company first reported a position in BCRX in Q1 2023 and held it in 9 quarters. The position peaked at $780K in Q4 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Empire Financial Management Company reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Empire Financial Management Company sold 100,000 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $780K.
  • Empire Financial Management Company first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 9 quarters.
  • Empire Financial Management Company's BioCryst Pharmaceuticals position peaked at $780K in Q4 2025.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Empire Financial Management Company's 13F filing for Q1 2026, filed 18 May 2026.